Gilead Sciences ( Gilead Sciences)

Primary tabs

Gilead Sciences's picture

Management

John C. Martin is the Chairman of the Company. He earned a bachelor's degree in chemical engineering from Purdue University and an MBA in marketing from Golden Gate University and a PhD in organic chemistry from the University of Chicago. John F. Milligan is the CEO of the Company.

Contact Address

Foster City, California, U.S.

About Gilead Sciences

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. We strive to transform and simplify care for people with life-threatening illnesses around the world. Gilead's portfolio of products and pipeline of investigational drugs includes treatments for HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular conditions. Gilead Sciences, Inc., commonly known as Gilead Sciences or Gilead (also styled GILEAD) /ˈɡɪliəd/, is an American biotechnology company that researches, develops and commercializes drugs. The company focuses primarily on antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi.

Gilead Sciences press release, blog etc

Thu, 12/12/2024 - 22:18 Gilead Sciences Appoints Dietmar Berger, MD, PhD, as Chief Medical Officer
Fri, 02/09/2024 - 16:19 Gilead Named One of Americas Most JUST Companies by JUST Capital and CNBC
Thu, 02/01/2024 - 21:15 Ted Love, MD, Joins Gilead Sciences Board of Directors
Fri, 12/23/2022 - 11:00 Gilead Enables Easier Veklury (Remdesivir) Access Through Retail and Specialty Pharmacies for Long-Term Care and Skilled Nursing Facilities
Thu, 11/03/2022 - 10:23 Gilead and Kite Oncology Demonstrate Transformative Impact of Cell Therapy and Promise of Blood Cancer Portfolio at ASH 2022
Fri, 09/30/2022 - 15:57 Gilead to Acquire All Remaining Rights to Potential First-in-Class Immunotherapy GS-1811 From Jounce Therapeutics
Fri, 09/30/2022 - 10:59 European Commission Grants Expanded Marketing Authorization for Gileads Biktarvy for the Treatment of HIV in Pediatric Populations
Fri, 09/30/2022 - 09:50 Kite and Arcellx Announce Strategic Collaboration to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma
Tue, 09/20/2022 - 14:04 Gilead Sciences Completes Acquisition of MiroBio
Wed, 08/17/2022 - 09:14 Gilead Sciences Announces Collaboration With Morehouse School of Medicine and Xavier University of Louisiana College of Pharmacy to Address Inequities in HIV Care
Wed, 07/27/2022 - 00:57 Gilead Sciences Statement on FDA Acceptance of New Drug Application for Investigational Lenacapavir
Tue, 07/19/2022 - 23:29 Gilead Sciences Contributes Additional $85 Million to Its Foundation to Advance Health Equity
Tue, 07/12/2022 - 05:59 Gilead Sciences Appoints Deborah Telman as Executive Vice President, Corporate Affairs and General Counsel
Thu, 06/30/2022 - 11:29 Kite and Refuge Biotechnologies Announce Exclusive License Agreement for Investigational Gene Expression Platform for Blood Cancers
Wed, 05/11/2022 - 19:40 FDA Lifts Clinical Hold on Investigational Lenacapavir for the Treatment and Prevention of HIV
Wed, 05/11/2022 - 11:12 Investigational Lenacapavir Receives Positive CHMP Opinion for People With Multi-Drug Resistant HIV
Thu, 03/31/2022 - 17:41 Gilead and Kite Oncology to Highlight Advances Supporting New Innovations in Cancer Care at the ASCO Annual Meeting
Thu, 03/31/2022 - 15:43 Gilead Resubmits New Drug Application to U.S. Food and Drug Administration for Lenacapavir, an Investigational, Long-Acting HIV-1 Capsid Inhibitor
more

InfoBox

Formation1987
HeadJohn F. Milligan
FounderJohn C. Martin
Employees10,000
LocationUnited States
HomePagewww.gilead.com/
LinkedInwww.linkedin.com/company/gilead-sciences
Wikipediaen.wikipedia.org/wiki/Gilead_Sciences